USPTO Examiner KIM TAEYOON - Art Unit 1631

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18948773PREPARATION METHOD OF MESENCHYMAL STEM CELL (MSC) AND APPLICATION THEREOF IN KNEE PRODUCTNovember 2024August 2025Abandon910NoNo
18436632HUMAN FIBROLAMELLAR HEPATOCELLULAR CARCINOMAS (hFL-HCCS)February 2024December 2025Abandon2201NoNo
18480956METHOD OF PRODUCING CANCER STEM CELLSOctober 2023September 2025Abandon2421NoNo
18459692CARDIAC STEM CELLS FOR CARDIAC REPAIRSeptember 2023May 2024Allow820YesNo
18240744CONTINUOUSLY BIOPRINTED MULTILAYER TISSUE STRUCTUREAugust 2023October 2025Allow2621NoNo
18129398Post-Natal Transplantation Of Factor VIII-Expressing Cells For Treatment of HemophiliaMarch 2023January 2026Allow3420YesNo
18192682GRAFT SCAFFOLD FOR CARTILAGE REPAIR AND PROCESS FOR MAKING SAMEMarch 2023April 2025Abandon2510NoNo
18190783BONE MARROW DERIVED NEUROKININ-1 RECEPTOR POSITIVE (NK1R+) MESENCHYMAL STEM CELLS FOR THERAPEUTIC APPLICATIONSMarch 2023October 2025Abandon3111NoNo
18123920METHODS FOR THE TREATMENT OF BETA-THALASSEMIAMarch 2023March 2025Abandon2310NoNo
18175154CARDIAC STEM CELLS FOR CARDIAC REPAIRFebruary 2023November 2024Allow2111YesNo
18112095METHOD OF CULTURING NK CELLS AND KITS CONTAINING MEDIUM ADDITIONSFebruary 2023February 2025Abandon2410NoNo
18041153USES OF MSC IN IMPROVING THROMBOTIC COMPLICATIONS IN COVID-19 PNEUMONIAFebruary 2023March 2026Abandon3701NoNo
18104924GENERATION OF A MESENCHYMAL STROMAL CELL BANK FROM THE POOLED MONONUCLEAR CELLS OF MULTIPLE BONE MARROW DONORSFebruary 2023November 2025Allow3321NoNo
18005051METHOD OF ENCAPSULATION OF AN ACTIVE PROTEIN USING ELECTRODEPOSITION TECHNIQUES, AN IMMUNOMODULATING COMPOSITION CONTAINING THE ACTIVE PROTEIN AND A POLYMER, AND ITS USE FOR THE PRODUCTION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ATOPIC DERMATITIS IN HUMANSJanuary 2023March 2026Abandon3801NoNo
18147269COMBINATION THERAPY COMPRISING A COMPOSITION OF MESENCHYMAL STROMAL CELLS AND HYALURONIC ACID FOR USE IN TREATMENT OF OSTEOARTHRITISDecember 2022February 2026Allow3810YesNo
18146142METHOD FOR EXPANSION OF DOUBLE NEGATIVE REGULATORY T CELLSDecember 2022March 2026Allow3810YesNo
18084206C-KIT-POSITIVE BONE MARROW CELLS AND USES THEREOFDecember 2022January 2025Abandon2510NoNo
18080373CELL CULTURE MEDIUM FOR EUKARYOTIC CELLSDecember 2022July 2023Allow710YesNo
18009605METHODS AND COMPOSITIONS FOR TREATING CORONAVIRUS INFECTIOUS DISEASEDecember 2022March 2026Abandon3901NoNo
18008911CELL/GENE THERAPIES TARGETING MAGE-A4 PEPTIDEDecember 2022March 2026Allow3910NoNo
17927940USE OF MRNAS ENCODING OX40L, IL-23 AND IL-36GAMMA FOR TREATING CANCERNovember 2022February 2026Abandon3801NoNo
17927335CELL-DERIVED VESICLE RICH IN PROTEIN HOMEOSTASIS REGULATORS AND METHOD OF PREPARING SAMENovember 2022February 2026Abandon3901NoNo
18057487TREATMENT OF PREMATURE BIRTH COMPLICATIONSNovember 2022December 2024Abandon2501NoNo
18053847CELL SHEET HAVING FIBROSIS INHIBITORY ACTIONNovember 2022January 2025Abandon2610NoNo
17981736METHOD FOR ENHANCING EXPRESSION OF INSULIN LIKE GROWTH FACTOR 1 RECEPTOR IN UMBILICAL CORD MESENCHYMAL STEM CELL EXPRESSING IGF1R AND METHOD FOR OBTAINING MULTIPOTENT UMBILICAL CORD MESENCHYMAL STEM CELLNovember 2022October 2024Allow2311NoNo
17923871METHOD FOR PRODUCING EXTRACELLULAR VESICLES COMPRISING FETUS-DERIVED PRIMAL IMMUNOGLOBULINNovember 2022July 2024Allow2021YesNo
18045137METHODS FOR CULTURING CELLS AND KITS AND APPARATUS FOR SAMEOctober 2022September 2025Abandon3621NoNo
17820473NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION THEREOFAugust 2022February 2026Abandon4210NoNo
17904433AAV CAPSID-PROMOTER INTERACTIONS AND CELL SELECTIVE GENE EXPRESSIONAugust 2022February 2026Abandon4201NoNo
17817757METHODS FOR DIFFERENTIATING MESENCHYMAL STEM CELLSAugust 2022December 2024Abandon2810NoNo
17873344Lymphocyte-Based Morphometric Test for Alzheimer's DiseaseJuly 2022May 2025Allow3420NoNo
17808423Vascular Extracellular Matrix HydrogelJune 2022September 2024Allow2710YesNo
17618104FPR2 RECEPTOR AGONIST APTAMERS AND USES THEREOFJune 2022December 2025Abandon4810NoNo
17784093GENE THERAPY OF HEMOPHILIA A USING VIRAL VECTORS ENCODING RECOMBINANT FVIII VARIANTS WITH INCREASED EXPRESSIONJune 2022December 2025Abandon4210NoNo
17737052USE OF VETO CELLS FOR THE TREATMENT OF SICKLE CELL DISEASEMay 2022November 2025Abandon4210NoNo
17774140METHODS OF MODULATING HAIR FOLLICLE STEM CELL QUIESCENCE BY MODULATING DERMAL NICHE ACTIVATOR GAS6May 2022November 2025Abandon4310NoNo
17732478USE OF HISTONE DEUBIQUITINASE IN PREPARING DRUG FOR PREVENTING AGING AND TREATING AGING-RELATED DISEASESApril 2022November 2025Abandon4310NoNo
17726833COMPOSITIONS AND METHODS FOR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHYApril 2022November 2025Abandon4301NoNo
17659157CELL POPULATIONS HAVING IMMUNOREGULATORY ACTIVITY, METHOD FOR ISOLATION AND USESApril 2022August 2024Allow2820NoNo
17658446CELL CULTURE BASE MATERIAL AND CELL CULTURE BASE MATERIAL WITH CELLSApril 2022November 2025Abandon4310NoNo
17702586Irradiation of Red Blood Cells and Anaerobic StorageMarch 2022May 2024Allow2610NoNo
17762690COMPOSITIONS AND METHODS FOR TREATMENT OF LIQUID CANCERSMarch 2022October 2025Allow4311YesNo
17642140USE OF GHOST NANOVESICLES AS THERAPEUTICSMarch 2022November 2025Allow4421YesNo
17691028STEM CELL COMPOSITIONMarch 2022March 2025Abandon3721NoNo
17677163CELL CULTURE MEDIUM FOR EUKARYOTIC CELLSFebruary 2022September 2022Allow720YesNo
17636317OLIGONUCLEOTIDE-BASED THERAPY FOR ULCERATIVE COLITISFebruary 2022November 2025Abandon4510NoNo
17581329NOVEL ANUCLEATED CELLS AND USES THEREOFJanuary 2022June 2024Abandon2840YesNo
17571116CELL THERAPEUTIC AGENT FOR ANTI-INFLAMMATORY OR DAMAGED TISSUE REGENERATION COMPRISING PRUSSIAN BLUE NANOPARTICLES, AND METHOD FOR PREPARING THE SAMEJanuary 2022September 2025Abandon4441NoNo
17556380MAPC TREATMENT OF BRAIN INJURIES AND DISEASESDecember 2021June 2025Abandon4110NoNo
17556330MAPC TREATMENT OF BRAIN INJURIES AND DISEASESDecember 2021January 2025Abandon3720NoNo
17594707PIM1 INHIBITORS FOR USE IN TREATMENT OF VIRAL INFECTION AND PHARMACEUTICAL COMPOSITIONS THEREOFOctober 2021March 2025Allow4110NoNo
17510717OPTIMIZED METHOD FOR LARGE SCALE PRODUCTION OF PARVOVIRUS H-1 IN AN ESSENTIALLY SERUM-FREE MEDIUMOctober 2021February 2025Abandon4020YesNo
17594661METHODS AND COMPOSITIONS FOR REPROGRAMMING MÜLLER GLIAOctober 2021July 2025Allow4511NoNo
17606410COMPOSITIONS USEFUL FOR TREATMENT OF POMPE DISEASEOctober 2021November 2025Abandon4920NoNo
17605719COMPOSITIONS AND METHODS OF MAKING EXPANDED HEMATOPOIETIC STEM CELLS USING DERIVATIVES OF CARBAZOLEOctober 2021January 2025Abandon3901NoNo
17503756METHOD FOR REPAIRING DAMAGED TISSUEOctober 2021April 2025Abandon4230NoNo
17500341BONE-LIKE PROSTHETIC IMPLANTSOctober 2021April 2024Abandon3011NoNo
17602922METHODS FOR PRODUCING REGULATORY B CELLS AND USES THEREOFOctober 2021September 2025Allow4720NoNo
17469553CRYOPRESERVATION METHODSeptember 2021September 2024Abandon3711NoNo
17436640IMMUNOMODULATING MESENCHYMAL STEM CELLSSeptember 2021June 2025Abandon4520NoNo
17467358LIVE CELL CONSTRUCTS FOR PRODUCTION OF CULTURED MILK PRODUCT AND METHODS USING THE SAMESeptember 2021February 2025Abandon4140YesYes
17434488AMNIOTIC FLUID-DERIVED EXTRACELLULAR VESICLES AND USES THEREOF FOR WOUND HEALINGAugust 2021August 2025Allow4731YesNo
17432758METHOD OF HOMING AND RETENTION OF GAMMADELTA T CELLS, OPTIONALLY WITH NATURAL KILLER CELLS, FOR GENERATING CELL COMPOSITIONS FOR USE IN THERAPYAugust 2021October 2025Abandon5011NoNo
17432011Compositions Comprising Microbial Polypeptides for Degrading Glycogen and Methods for the Treatment of Glycogen Storage DiseasesAugust 2021December 2025Allow5221NoNo
17430055COMPOSITIONS AND METHODS FOR ENHANCED LYMPHOCYTE-MEDIATED IMMUNOTHERAPYAugust 2021November 2025Allow5121YesNo
17427393OLIGONUCLEOTIDE MOLECULE AND APPLICATION THEREOF IN TUMOR THERAPYJuly 2021May 2025Abandon4511NoNo
17381192METHOD FOR EX VIVO EXPANSION OF REGULATORY T CELLSJuly 2021January 2025Abandon4210NoNo
17423236A METHOD OF GENE EDITINGJuly 2021February 2025Abandon4301NoNo
17373089IMMUNOMODULATORY PROPERTIES OF MULTIPOTENT ADULT PROGENITOR CELLS AND USES THEREOFJuly 2021December 2024Abandon4120NoNo
17363154METHOD OF PREPARING MESENCHYMAL-LIKE STEM CELLS AND MESENCHYMAL-LIKE STEM CELLS PREPARED THEREBYJune 2021March 2024Abandon3260YesNo
17419239CAR T CELL METHODS AND CONSTRUCTSJune 2021June 2025Abandon4811NoNo
17413392ANELLOSOMES AND METHODS OF USEJune 2021January 2026Allow5521NoNo
17344205MAPC TREATMENT OF BRAIN INJURIES AND DISEASESJune 2021April 2024Allow3410NoNo
17339440ENHANCED STEM CELL COMPOSITIONJune 2021March 2024Abandon3310NoNo
17319760VIABLE BIOENGINEERED SKIN CONSTRUCTSMay 2021May 2024Abandon3620NoNo
17302855METHODS AND COMPOSITIONS FOR TREATMENT OF BONE DEFECTS WITH PLACENTAL CELL POPULATIONSMay 2021March 2024Abandon3411NoNo
17291936T Cells with Improved Mitochondrial FunctionMay 2021October 2024Abandon4201NoNo
17242575FORMULATIONS AND METHODS FOR ACTIVATING SIGNALING MOLECULES OUTSIDE A NATIVE PHYSIOLOGICAL RESPONSEApril 2021December 2023Abandon3111NoNo
17243173siNA MOLECULES, METHODS OF PRODUCTION AND USES THEREOFApril 2021October 2023Abandon2901NoNo
17238760NEURAL CELL EXTRACELLULAR VESICLESApril 2021June 2024Allow3850YesYes
17233783METHOD FOR CULTURING A SUBPOPULATION OF CIRCULATING EPITHELIAL TUMOUR CELLS FROM A BODY FLUIDApril 2021October 2023Allow3011YesNo
17284212USES OF MODIFIED RNA ENCODING RETINALDEHYDE DEHYDROGENASEApril 2021August 2025Abandon5221YesNo
17226769IMMUNOMODULATORY PROPERTIES OF MULTIPOTENT ADULT PROGENITOR CELLS AND USES THEREOFApril 2021June 2024Abandon3920NoNo
17217065HUMAN UMBILICAL CORD BLOOD MESENCHYMAL STEM CELL TRANSFUSION IMMUNOTHERAPY FOR TREATMENT OF CYTOKINE STORM ASSOCIATED WITH CORONAVIRUS INFECTIONMarch 2021July 2024Abandon3931NoNo
17212480Engineered Renal Tissues, Arrays Thereof, and Methods of Making the SameMarch 2021August 2023Allow2910NoNo
17207401MITOCHONDRIAL AUGMENTATION THERAPY OF RENAL DISEASESMarch 2021November 2024Abandon4480YesNo
17275057POLYNUCLEOTIDES ENCODING URIDINE DIPHOSPHATE GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1 FOR THE TREATMENT OF CRIGLER-NAJJAR SYNDROMEMarch 2021April 2025Abandon4911NoNo
17191526CARDIAC STEM CELLS FOR CARDIAC REPAIRMarch 2021January 2023Allow2340YesNo
17147167IMMUNOMODULATORY PROPERTIES OF MULTIPOTENT ADULT PROGENITOR CELLS AND USES THEREOFJanuary 2021October 2024Abandon4620NoYes
16950751METHODS OF REPROGRAMMING SOMATIC CELLS AND MATERIALS RELATED THERETONovember 2020March 2025Abandon5231NoNo
17053597CAR-T CELLS EXPRESSING AN INHIBITORY ANTI-TGF-BETA-RECEPTOR II SINGLE DOMAIN ANTIBODYNovember 2020April 2024Abandon4101NoNo
17065364METHODS AND COMPOSITIONS FOR HEMATOPOIETIC STEM CELL MOBILIZATIONOctober 2020April 2024Allow4221YesNo
17044045MATERIALS AND METHODS FOR THE TREATMENT OF LEWY BODY DISORDERSSeptember 2020January 2026Allow6041NoNo
17006257ISOLATION, CULTIVATION AND USES OF STEM/PROGENITOR CELLSAugust 2020March 2024Abandon4330NoNo
16996924Cellular pharmaceutical product containing quantified doubling level stem cells and a method for producing itAugust 2020March 2023Abandon3110NoNo
16969558ALLOGENEIC COMPOSITIONAugust 2020April 2025Abandon5641YesNo
16991902STEM CELL PREPARATION RESISTING HYPOXIA INJURY, PREPARATION METHOD THEREFOR, AND USE THEREOF IN PREPARATION OF MEDICAMENT FOR TREATING ACUTE MYOCARDIAL INFARCTIONAugust 2020July 2024Abandon4721YesNo
16963974DEVICE AND METHOD FOR FREEZE DRYING BIOLOGICAL SAMPLESJuly 2020March 2024Abandon4401NoNo
16931003METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLSJuly 2020April 2024Allow4521YesNo
16918979MESENCHYMAL STEM CELLS OR STROMAL CELLS HARBORING MODIFIED RNAS ENCODING VEGF AND BMP POLYPEPTIDESJuly 2020March 2023Abandon3301NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KIM, TAEYOON.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
4
Examiner Affirmed
3
(75.0%)
Examiner Reversed
1
(25.0%)
Reversal Percentile
37.7%
Lower than average

What This Means

With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
22
Allowed After Appeal Filing
3
(13.6%)
Not Allowed After Appeal Filing
19
(86.4%)
Filing Benefit Percentile
16.4%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 13.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner KIM, TAEYOON - Prosecution Strategy Guide

Executive Summary

Examiner KIM, TAEYOON works in Art Unit 1631 and has examined 162 patent applications in our dataset. With an allowance rate of 55.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 45 months.

Allowance Patterns

Examiner KIM, TAEYOON's allowance rate of 55.6% places them in the 16% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by KIM, TAEYOON receive 2.94 office actions before reaching final disposition. This places the examiner in the 85% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by KIM, TAEYOON is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +42.0% benefit to allowance rate for applications examined by KIM, TAEYOON. This interview benefit is in the 88% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 16.7% of applications are subsequently allowed. This success rate is in the 13% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 33.7% of cases where such amendments are filed. This entry rate is in the 50% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 55.6% of appeals filed. This is in the 27% percentile among all examiners. Of these withdrawals, 40.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 107.8% are granted (fully or in part). This grant rate is in the 94% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 8.6% of allowed cases (in the 92% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.